This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Basilea Pharmaceutica AG

Drug Names(s): BAL5788, ceftobiprole medocaril, Mabelio, Zevtera (EU)

Description: Ceftobiprole is a fifth-generation cephalosporin. The fifth generation cephalosporins are notably differentiated from earlier generations by their activity against methicillin-resistant Staphylococcus aureus. They also exhibit modest activity against Enterococcus faecalis, a further differentiation from earlier generation cephalosporins.

Like other cephalosporins, Ceftaroline targets penicillin-binding proteins (PBPs) to inhibit the synthesis of the bacterial cell wall, and has a high affinity for PBP2', which occurs in MRSA.

Deal Structure: Basilea and Cilag
In February 2005, Basilea Pharmaceutica entered into an exclusive worldwide agreement with Cilag, a Johnson & Johnson company, to develop, manufacture and market ceftobiprole. Under the terms of the agreement, Basilea will receive a substantial upfront payment and is eligible for additional payments on achievement of pre-specified clinical, regulatory and sales milestones. Upfront and milestone payments may together total up to 370 million Swiss Francs. Basilea will also receive significant double-digit royalties on worldwide sales. Ortho-McNeil Pharmaceutical, another Johnson & Johnson company, will market ceftobiprole in the U.S. and its affiliate companies, known as Janssen-Cilag, will market the product outside the U.S. Basilea has retained an option to co-promote ceftobiprole in the U.S., in major European countries, Japan and China. Ortho-McNeil's research affiliate, Johnson & Johnson Pharmaceutical Research and Development, will develop...See full deal structure in Biomedtracker

Partners: Quintiles Transnational Holdings, Inc. Hikma Pharmaceuticals plc Biotoscana International

Zeftera News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug